Evidence map›Paper›PMID 29088364›Full record

ArticleAge and ageing2017

Inception and deprescribing of statins in people aged over 80 years: cohort study.

Martin Gulliford, Rathi Ravindrarajah, Shota Hamada, Stephen Jackson, Judith Charlton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Age and ageing, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Current Landscape and Future Directions of Deprescribing and Polypharmacy Practices in Jordan.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Statin discontinuation in persons with and without Alzheimer's disease.European journal of clinical pharmacology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Observational
  16. Review
  17. Article
  18. Review of the top 5 geriatrics studies of 2018-2019.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin GullifordKing's College London, Department of Primary Care and Public Health Sciences, London, UK.
Rathi RavindrarajahKing's College London, Department of Primary Care and Public Health Sciences, London, UK.
Shota HamadaKing's College London, Department of Primary Care and Public Health Sciences, London, UK.
Stephen JacksonKing's College London, Department of Clinical Gerontology, London, UK.
Judith CharltonKing's College London, Department of Primary Care and Public Health Sciences, London, UK.

Funding

The Dunhill Medical Trust R392/1114
6 · The paper itself

Abstract

Objective: statin use over the age of 80 years is weakly evidence-based. This study aimed to estimate rates of statin inception and deprescribing by frailty level in people aged 80 years or older. Methods: a cohort of 212,566 participants aged ≥80 years was sampled from the UK Clinical Practice Research Datalink. Statin inception was defined as a first-ever prescription in a non-statin user; deprescribing was defined as a last ever statin prescription more than 6 months before the end of participant records. Rates were estimated in a time-to-event framework allowing for mortality as a competing risk. Co-variates were age, gender, frailty category and prevention type. Results: prevalent statin use increased from 2001-5 (9.9%) to 2011-15 (49.3%). Inception of statins in never-users was low overall at 2.4% per year (95% confidence interval (CI) 2.2-2.6%) and declined with age. Deprescribing of statins in current users occurred at a rate of 5.6% (95% CI 5.4-5.9%) per year overall and increased with age, reaching 17.8% per year (95% CI 6.7-28.9%) among centenarians. Deprescribing was slightly higher for primary prevention (6.5% per year) than secondary prevention (5.2% per year) indications (P < 0.001). Deprescribing increased with frailty level being 5.0% per year in 'fit' participants and 7.1% in 'severe' frailty (P < 0.001). Conclusions: statin use has increased in the over 80s but deprescribing is common and increases with age and frailty level. These paradoxical findings highlight a need for better evidence to inform statin use and discontinuation for people aged ≥80 years.

Indexed as

Aged, 80 and overAge FactorsAgingBiomarkersCardiovascular DiseasesDatabases, FactualDrug PrescriptionsDyslipidemiasFemaleFrail ElderlyHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipidsMalePractice Patterns, Physicians'Primary PreventionBiomarkersHydroxymethylglutaryl-CoA Reductase InhibitorsLipids80 and overcardiovascular diseasefrailtyolder peopleprimary carestatin therapy

Identifiers

PMID29088364
PMCPMC5669477

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.